Could HIV, the virus that causes AIDS, be weakening The results of a study conducted in Belgium, at the Institute of Tropical Medicine in Antwerp, seem to suggest that in one corner of the world it might be. The report, published in the latest issue of AIDS, a specialist journal, concludes that HIV’s ability to replicate (known technically as its virulence) may have decreased since the start of the pandemic. Kevin Aden, the lead author of the paper, stresses that the study is based on a small set of samples and does not prove that HIV’s virulence is attenuating around the world. However, it does offer new insights into the evolution of the disease.
Dr. Arien looked at 24 blood samples collected from untreated patients attending an HIV/ AIDS clinic in Antwerp. A dozen of these samples were taken between 1986 and 1989; the other 12 were collected between 2002 and 2003. First, he analyzed the samples to find their viral load (the number of virus particles per cub
A. weakening.
B. accentuating.
C. accelerating.
D. increasing.
Bristol-Myers Squibb and Gilead Sciences have combined many HIV drugs into a single pill. Sometimes the best medicine is more than one kind of medicine. Malaria, tuberculosis and HIV/ AIDS, for example, are all treated with (1) of drugs. But that can mean a lot of pills to take. It would be (2) if drug companies combined all the medicines into a single pill, taken just once a day.
Now, two companies say they have done that for people just (3) treatment for HIV, the virus that causes AIDS. The companies are Bristol-Myers Squibb and Gilead Sciences. They have (4) a single pill that combines three drugs currently on the market. Bristol-Myers Squibb sells one of them (5) the name of Sustiva. Gilead combined the (6) , Emtriva and Viread, into a single pill in two thousand four.
Combining drugs involves more than (7
A. one
B. ones
C. other
D. others
我来回答:
